Table 2 Efficiency of the different formulations against M. tuberculosis H37Rv-GFP extracellular or intramacrophage replication.

From: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles

Formulation

Extracellular assay IC50 (µg/mL) ± SD

Intracellular assay IC50 (µg/mL) ± SD

Controls (DMSO)

ETH

0.30 ± 0.10

0.11 ± 0.01

[ETH:Booster]

0.11 ± 0.06

0.06 ± 0.02

PLA NPs (Nanoemulsion)

PLA::ETH

0.12 ± 0.04

0.09 ± 0.05

PLA::[ETH:Booster]

0.06 ± 0.02

0.04 ± 0.02

pCD NPs

pCD::ETH

0.13 ± 0.04

0.06 ± 0.01

pCD::[ETH:Booster]

0.06 ± 0.02

0.04 ± 0.01

  1. Results, expressed as concentration of ETH required to inhibit 50% of the bacterial growth in µg/mL (IC50), were calculated by nonlinear regression analysis using the equation for a sigmoidal dose-response curve with variable slope using the GraphPad Prism 5.0 software. Results are shown as the mean ± standard deviation of three independent experiments.
Back to article page